Why one company thinks a 486% price hike for its drug is justified; Cancer vaccines gain momentum, after years of disappointing results

Taking stock of the drug industry, from the lab to the medicine chest

April 10, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | Did you say 486%? Why one company thinks such a price hike for its drug is justified Harrow argues its eye treatment, which has been out of stock for years, is underpriced and requires substantial investment in manufacturing. By Ed Silverman STAT+ | Cancer vaccines gain momentum, after years of disappointing results Data from two early-stage clinical trials hint that cancer vaccines might be used to prevent or lower the risk of relapse after surgery. By Angus Chen STAT+ | BIO's top lobbyist exits, signaling reorganization The departure of Nick Shipley may be part of a greater shakeup spearheaded by BIO's new CEO, John Crowley. By Rachel Cohrs and John Wilkerson Sandy Huffaker for STAT STAT+ | Vertex to buy Alpine Immune Sciences for $4.9 billion The acquisition gives Vertex a drug called povetacicept, which has shown promise in treating IgA nephropathy, an autoimmune disorder. By Matthew Herper and Adam Feuerstein

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser